Search results
In the Wake of 'Amgen v. Sanofi,' the USPTO Clarifies the Patent Enablement Requirement | The Legal...
Law.com· 8 hours agoThe Supreme Court unanimously affirmed the determination that Amgen’s claims covering a genus of...
The Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger...
Zacks via Yahoo Finance· 10 hours agoStocks recently featured in the blog include: Apple Inc. AAPL, Mastercard Inc. MA, Amgen Inc. AMGN,...
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
ETF DAILY NEWS· 5 days agoPanagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most ...
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient...
Benzinga via Yahoo Finance· 4 days agoSunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase...
Recent Insider Activity Could Benefit AMGEN Inc.
Knox Daily· 3 days agoAMGEN Inc.’s recent filing unveils that its SVP & CCO Grygiel Nancy A. unloaded Company’s shares for reported $0.66 million on May 03 ’24. In the deal valued at $313.09 per ...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli...
Zacks via Yahoo Finance· 5 days agoStocks recently featured in the blog include: Novo Nordisk NVO, Eli Lilly’s LLY, Viking Therapeutics...
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
InvestorPlace· 12 hours agoInvesting in Dow stocks is always a reasonable strategy for those who value the American economy....
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value
Guru Focus· 4 days agoIn this article, we will take a look into Amgen Inc's (AMGN) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of usi
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Motley Fool via Yahoo Finance· 6 days agoLilly dominates the weight loss scene along with Novo Nordisk, a maker of two drugs that function in...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoAmgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe ...
